Company: HRTX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-028374
Chunk: 127

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1B
Chunk 127
---
 31, 2024, total inventory included $11.8 million related to ZYNRELEF, $36.6 million related to CINVANTI, $3.2 million related to SUSTOL and $1.6 million related to APONVIE. As of December 31, 2023, total inventory included $11.2 million related to ZYNRELEF, $26.4 million related to CINVANTI, $4.1 million related to SUSTOL and $0.4 million related to APONVIE. Cost of product sales for the years ended December 31, 2024 and 2023 included charges of $2.5 million and $20.3 million, respectively, relating to the reserves and write-offs of inventory.Prepaid Expenses and Other AssetsPrepaid expenses and other assets consist of the following (in thousands): 

        December 31,

        2024

        2023

        Prepaid expenses
         
        $
        21,224

        $
        11,731

        Prepaid insurance

        2,203

        1,910

        Deposits

        274

        274

        Interest receivables

        263

        310

        Other receivables

        209

        21

        Total prepaid expenses and other assets
         
        $
        24,173

        $
        14,246

      Property and EquipmentProperty and equipment, net consists of the following (in thousands): 

        December 31,

        2024

        2023

        Scientific equipment
         
        $
        30,342

        $
        34,027

        Leasehold improvements

        307

        647

        Computer equipment and software

        1,047

        1,506

        Furniture, fixtures and office equipment

        1,014

        1,014

        Property and equipment, gross

        32,710

        37,194

        Less: accumulated depreciation and amortization

        (17,847
        )

        (17,028
        )

        Property and equipment, net
         
        $
        14,863

        $
        20,166

      Depreciation and amortization expense for the years ended December 31, 2024 and 2023 was $2.5 million and